- Home
- NNBR vs EPRX Comparison
NNBR vs EPRX Comparison
Compare NNBR & EPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNBR
- EPRX
- Stock Information
- Founded
- NNBR 1980
- EPRX 2011
- Country
- NNBR United States
- EPRX Canada
- Employees
- NNBR N/A
- EPRX N/A
- Industry
- NNBR Industrial Machinery/Components
- EPRX
- Sector
- NNBR Industrials
- EPRX
- Exchange
- NNBR Nasdaq
- EPRX NYSE
- Market Cap
- NNBR 111.0M
- EPRX 137.7M
- IPO Year
- NNBR 1994
- EPRX N/A
- Fundamental
- Price
- NNBR $2.31
- EPRX $5.39
- Analyst Decision
- NNBR
- EPRX Strong Buy
- Analyst Count
- NNBR 0
- EPRX 1
- Target Price
- NNBR N/A
- EPRX $12.00
- AVG Volume (30 Days)
- NNBR 544.4K
- EPRX 13.0K
- Earning Date
- NNBR 08-06-2025
- EPRX 08-07-2025
- Dividend Yield
- NNBR N/A
- EPRX N/A
- EPS Growth
- NNBR N/A
- EPRX N/A
- EPS
- NNBR N/A
- EPRX N/A
- Revenue
- NNBR $448,780,000.00
- EPRX N/A
- Revenue This Year
- NNBR N/A
- EPRX N/A
- Revenue Next Year
- NNBR $4.96
- EPRX N/A
- P/E Ratio
- NNBR N/A
- EPRX N/A
- Revenue Growth
- NNBR N/A
- EPRX N/A
- 52 Week Low
- NNBR $1.58
- EPRX $2.20
- 52 Week High
- NNBR $4.67
- EPRX $6.20
- Technical
- Relative Strength Index (RSI)
- NNBR 60.84
- EPRX N/A
- Support Level
- NNBR $1.80
- EPRX N/A
- Resistance Level
- NNBR $2.32
- EPRX N/A
- Average True Range (ATR)
- NNBR 0.14
- EPRX 0.00
- MACD
- NNBR 0.03
- EPRX 0.00
- Stochastic Oscillator
- NNBR 98.08
- EPRX 0.00
About NNBR NN Inc.
NN Inc is a diversified industrial company that combines engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision solutions and components. It operates in two business segments: mobile solutions and power solutions. The mobile solutions segment involves growth in the general industrial and automotive end markets. Its power solutions segment involves growth in the electrical and aerospace and defense end markets.
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.